( odiscover develop manufacture and co...)Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention,Health

o discover, develop, manufacture and commercialize PARP inhibitors, including INO-1001, for the potential treatment of cancer. Additionally, Genentech has retained an option to develop and commercialize Inotek's PARP inhibitors to prevent cell death and complications associated with various acute cardiovascular conditions and procedures. Inotek has retained all rights to develop and commercialize PARP inhibitors outside of cancer and the specific acute cardiovascular diseases included in Genentech's option. A number of oral and intravenous next generation PARP inhibitors are in development for various disease states, including cancer.

About Inotek Pharmaceuticals

Inotek Pharmaceuticals Corporation (www.inotekcorp.com) is a Phase 2, drug-development company with a deep pipeline of small molecule compounds targeting the key biological processes involved in cell survival and tissue injury. Inotek's three platform programs have resulted in six novel molecules in various stages of preclinical and clinical development that target: 1) PARP, a nuclear enzyme that is fundamental to DNA repair and inflammation; 2) peroxynitrite, a highly toxic oxidative and nitrosative species produced by cells in response to injury; and 3) the purinergic receptor family, with a specific focus on adenosine receptors.

Inotek was founded in 1996 and currently has 140 employees, located in its corporate headquarters and main research laboratories in Beverly, Massachusetts and its clinical operations and GMP production facilities in Israel. Inotek has developed integrated capabilities from early discovery through Phase 2 clinical development.

Contact

Inotek Pharmaceuticals Corporation
Jeffrey T. Walsh, w 978-232-9660 x2388
Chief Business Officer
m 978-201-9129
or
Media:
MacDougall Biomedical Communications, Inc.
Kari Watson, 508-647-0209
Vice President
k
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Inotek Pharmaceuticals Announces Publication of Animal Data from Study of PARP Inhibition as Potential Preventative of Brain Injury Following Stroke
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies